Integrum Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Integrum (STO:INTEG B) Second Quarter 2025 Results

Key Financial Results

• Revenue: kr23.6m (down 31% from 2Q 2024).
• Net loss: kr8.95m (down by 331% from kr3.88m profit in 2Q 2024).
• kr0.46 loss per share (down from kr0.22 profit in 2Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Integrum Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 11% from a week ago.

Risk Analysis

Be aware that Integrum is showing 4 warning signs in our investment analysis and 1 of those can't be ignored...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.